CD8A and neoplasm: Immunotherapies using CD73 monocular antibody show great potential for immune anti-tumor therapy, and its combination with tartgeing PD1/PD-L1 sigalling achieved a remarkable synergy based on IFN-γ and CD8+ T cells [32, 33].